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As most studies on pemphigus vulgaris (PV) pathogenesis concern its active stage, we aimed to evaluate the serum concentration
of TNF-α, IL-1, and IL-6 in PV patients in clinical remission. The study group consisted of sera from 19 PV patients in active stage
and from 24 patients in clinical remission. 19 sera taken from healthy subjects served as the controls. Serum IL-6 concentrations in
PV active and PV remission group were signiﬁcantly higher when compared to the controls (P<. 05). In patients in active stage of
PV, a signiﬁcant correlation between serum IL-1 and IL-6 concentrations was found (rP = 0.46;P<. 0 5 ) .W ea l s of o u n dan e g a t i v e
correlation between TNF-αlevelandpemphigusantibodiestiterinthepatientsfromtheremissiongroup(rS =− 0.47303;P<. 02).
Our data suggest that IL-6 and TNF-α may be involved in maintaining immunological disturbances in remission stage of PV.
Copyright © 2008 Joanna Narbutt et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Pemphigus is an autoimmune blistering disease, charac-
terisedbysevereandchroniccourse.Basedonclinicalpicture
and proﬁle of circulating pemphigus antibodies, two distinct
forms of the disease are distinguished: pemphigus vul-
garis (PV) and pemphigus foliaceus (PF). Transmembrane
desmosomal proteins: desmoglein 1 (Dsg1) and desmoglein
3 (Dsg3) are pemphigus target antigens. In serum of PF
patients, anti-Dsg1 antibodies are detected while in PV
patients—antibodies are directed against Dsg3. However,
in approximately 50% of the latter cases, also anti-Dsg1
antibodies may be found. Binding of pemphigus antibodies
to the target antigens leads to the failure in adhesive
function of desmogleins, and in consequence to disruption
of desmosomes and thus acantholysis development [1].
Despite numerous investigations performed all over the
world, the exact mechanism of acantholysis has not been
fullyelucidated.Recentstudiespointoutatproinﬂammatory
cytokines such as TNF-α, IL-1, or IL-6 as strong players
involved in this process. Moreover, experimental studies
revealed that synergistic cooperation of pemphigus antibod-
ies with Fas-L and TNF-α results in acantholysis. Increased
mRNA expression for TNF-α and enhanced cytokine’s level
in serum of PV patients were observed by many authors
[2–4]. Furthermore, experimental models showed that mice
lacking TNF-α receptor are less sensitive to pemphigus
development after passive transfer of pemphigus antibodies
[2]. The above data at least in part explain therapeutic
eﬃcacy of anti-TNF-alpha antibodies in pemphigus vulgaris
treatment [5, 6].
Despite extensive research, the objective criteria of
complete cure in PV have not been deﬁned so far.
Direct immunoﬂuorescence (DIF) test detecting in vivo IgG
deposits bound in the intercellular spaces of the epidermis
and indirect immunoﬂuorescence (IIF) test demonstrating
circulating IgG antibodies are routine examinations in pem-
phigus diagnosis and their negative ﬁndings may indicate
treatment cessation. In some cases, however, despite a long-
lasting treatment and lack of clinical symptoms, either both
immunological examinations are still positive, or DIF test
is negative, but circulating antibodies are still detected. It
seems controversial, especially because most dermatologists
assume a strong correlation between the titre of pemphigus2 Mediators of Inﬂammation
antibodies and the disease activity. Most studies on PV
pathogenesis are focused on immunological disturbances in
active stage of the disease.
Thus, the aim of our study was to evaluate the serum
concentration of TNF-α, IL-1, and IL-6 in PV patients both
in active stage of the disease and in clinical remission and
assess their potential inﬂuence on disease course. We also
assessed the correlation between cytokines’ serum levels and
titer of pemphigu s antibodies.
2. MATERIAL AND METHODS
The study group consisted of 19 sera obtained from PV
patients in active stage of the disease and 24 sera obtained
from patients in clinical remission. Sera from active PV
patients had been collected before immunosuppressive treat-
ment; (prednisone+cyclophosphamide) was introduced. 19
sera taken from healthy unrelated subjects, age and sex
matched served as controls. Pemphigus vulgaris diagnosis
was based on the clinical picture and results of histological
andimmunologicalexaminations.Theseraofallthepatients
andindividualsfromthecontrolgroupwereexaminedbyIIF
on commercially available substrate of monkey esophagus
(Euroimmune, Lubeka, Germany), using a standard proce-
dure [7]. The same sera samples were examined by ELISA
(MESACUP Desmoglein Test Dsg1 and Dsg3; MBL Co. Ltd,
Nagoya , Japan) according to the manufacturer’s instruction.
ELISA index was assessed as positive when it was higher than
cutoﬀ (for Dsg 1–14; for Dgs 3–7).
All the patients’ direct immunoﬂuorescence (DIF) tests
revealed in vivo IgG and/or C3 deposits bound in the inter-
cellular spaces of the epidermis. Active stage of the disease
was considered when all the examinations were positive,
blisters and erosions on the mucous membranes and/or skin
were present. Sera samples were taken before introducing
immunosuppressive treatment. Clinical remission was con-
sidered when patients were treated with prednisone (20–
40mg every other day) and cyclophosphamide (50mg every
other day) and demonstrated lack of clinical lesions for at
least six months, while DIF and IIF still gave positive results.
The same sera samples were used to measure TNFα,
IL-1, and IL-6 levels using commercially available ELISA
kits (R & D, Minneapolis, Minn, USA), according to manu-
facturer’s procedure.
3. STATISTICAL ANALYSIS
Statistical analysis was performed using Statistica v.0.5 and
GraphPad Prism v.4.03. As laboratory data did not ﬁt a
Gaussian distribution according to Shapiro-Wilk test, all
results were expressed as median (50th) and interquartile
range (25th–75th), and nonparametric tests were used to test
statistical signiﬁcance. To avoid errors inherent in repeated
application of Mann-Whitney U tests, the Kruskal-Wallis
test was performed to make simultaneous comparison of
the assay data from each group, and to determine whether
there was a signiﬁcant variation in the medians of the groups
analysed. If this achieved 95% signiﬁcance, Dunn’s multiple
comparison posttest was then used to compare the assay
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Figure 1: Interleukin-1 (IL-1) concentration in serum samples
from patients with active stage of pemphigus vulgaris (PV active),
remission stage of PV (PV remission), and in normal controls. Box
plots with upper and lower bars showing the data range, and upper,
middle, and lower lines in the box showing 75th, 50th (median),
and 25th centiles, respectively.
results of one group with the other. For correlation studies,
the Pearson’s correlation or Spearman’s rank correlation was
used. In all calculations, P<. 05 was regarded as statistically
signiﬁcant.
4. RESULTS
Indirect immunoﬂuorescence test revealed circulating pem-
phigus antibodies in all PV patients. In the subjects from
active stage of the disease, antibodies titers ranged from
1:80 to 1:2560 (median 1:640) while in the patients from
remission group from 1:20 to 1:1280 (median 1:80).
Median serum concentrations of IL-1, IL-6, and TNF-
α in all the examined patients are presented in Table 1 and
Figures 1–3. IL-1 serum concentrations in the PV patients
from active and remission groups did not signiﬁcantly
diﬀer from the controls. IL-1 concentration in the PV
remission group was higher than in the PV active group,
however, this did not reach statistical signiﬁcance. Serum
IL-6 concentrations in PV active and PV remission group
were signiﬁcantly higher when compared to the controls. IL-
6 levels presented slightly higher values in the active group
in comparison to the remission group, but the diﬀerence
alsodidnotreachstatisticalsigniﬁcance.SerumTNF-αlevels
did not diﬀer signiﬁcantly between PV active group, PV
remission group and the control. The obtained values also
did not diﬀer between PV active and PV remission groups.
A signiﬁcant correlation between serum IL-1 and IL-6
concentrations in patients presenting active stage of PV was
found (rp = 0.46;P<. 05) (see Figure 4). No similar relation
wasobservedforthepatientsintheremissionstageofPV.We
also did not ﬁnd any signiﬁcant correlations between serum
concentration of IL-1 and TNF-α or IL-6 and TNF-α in all
the studied groups.
When analysing correlations between titer of circulating
pemphigus antibodies and serum concentrations of the
examinedcytokines,wefoundanegativecorrelationbetweenJ o a n n aN a r b u t te ta l . 3
Table 1: Interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) concentrations in serum samples from patients
with active stage of pemphigus vulgaris (PV active), remission stage of PV (PV remission), and in normal controls.
Cytokines PV active N = 19 PV remission N = 24 Controls N = 19
IL-1 (pg/mL)
Median 0.3 0.5 0.3
(Interquartile range, 25th–75th) 0.1–0.7 0.3–0.7 0.1–0.4
IL-6 (pg/mL)
Median 3.38 2.58 1.97
(Interquartile range, 25th–75th) 2.72–4.98 2.085–3.86 1.64–2.25
TNF-α (pg/mL)
Median 6.2 53.05 3.9
(Interquartile range, 25th–75th) 4.1–100 2.8–100 3.4–5.6
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Figure 2: Interleukin-6 (IL-6) concentration in serum samples
from patients with active stage of pemphigus vulgaris (PV active),
remission stage of PV (PV remission), and in normal controls. Box
plots with upper and lower bars showing the data range, and upper,
middle, and lower lines in the box showing 75th, 50th (median),
and 25th centiles, respectively. Kruskal-Wallis test across all three
groups P<. 0001. Only signiﬁcant Dunn’s multiple comparison
posttest p values between groups are shown.
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Figure 3:Tumornecrosisfactor-α(TNF-α)concentrationinserum
samples from patients with active stage of pemphigus vulgaris
(PV active), remission stage of PV (PV remission), and in normal
controls. Box plots with upper and lower bars showing the data
range, and upper, middle, and lower lines in the box showing 75th,
50th (median), and 25th centiles, respectively.
TNF-α level and antibodies titer in the patients from the
remission group (rS =− 0.47303;P<. 02).
5. DISCUSSION
Pemphigus vulgaris is a life-threatening disease of autoim-
mune background. During last decades, its pathogenesis has
been widely investigated and new insight into mechanisms
triggeringdiseasedevelopmentandproductionofantibodies
has been recognised. Despite the fact of that detection of
circulating and bound in vivo IgG pemphigus antibodies is
that main immunological feature, current knowledge point
out at involvement not only humoral but also cellular
immunological response in pemphigus development. It was
shown that Dsg3-speciﬁc lymphocytes T proliferate under
desmoglein 3 stimulation release Th2-dependent cytokines
such as IL-4 and IL-10 and demonstrate ability to modulate
activity of B cells [8, 9]. Although it is obvious that
autoimmune response in PV is T cell-mediated, the exact
role of those cells in acantholysis development has not
been elucidated yet. IL-2 is one of the main activators
of T lymphocytes. Increased values of soluble receptor
f o rI L - 2( s I L - 2 R )w e r ed e t e c t e di ns e r ao fp a t i e n t sw i t h
pemphigus, and these values correlated with activity of
the disease. However, their concentrations were signiﬁcantly
higher in blister ﬂuid thus suggesting presence of activated
T cells in PV skin lesions [10]. It was also proven that
isolated T lymphocytes from PV patients are required for
induction of histological and immunological phenomena in
the animal models of pemphigus [11]. Passive transfer of
pemphigus antibodies into hairless mice genetically thymus
deﬁcient caused their binding in intercellular spaces of the
epidermis,howeverblisterformationoverthebasementlayer
of epidermis was observed in less than 20% of cases. It is
another proof for an important role of lymphocytes T in
acantholysis development [12].
Keratinocytes stimulated with serum obtained from PV
patients presented higher expression of mRNA for IL-1α,
TNF-α, and urokinase plasminogen activator (uPA) and
developed acantholysis. When antibodies against these pro-
teins were used in these experiments, the authors observed a
signiﬁcant inhibition of acantholysis [2, 13]. Alecu et al. [14]4 Mediators of Inﬂammation
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Figure 4: Correlation between serum concentrations of IL-1 and
IL-6 in patients with active stage of PV.
found increased levels of ICAM-1, TNF-α, and IL-6 in sera
andblisterﬂuidobtainedfromPVpatients.Theaboveresults
seem to at least in part conﬁrm the role of these proteins in
PV development. Similar results were obtained by D’Auria
et al. and L´ opez-Robles et al. [3, 4] who showed increased
serum levels and in situ expression of IL-6 and TNF-α.I n
experimental models, it was also demonstrated that IL-1α
and TNF-α were able to activate C3 mRNA in keratinocytes
cultureafterstimulationwithpemphigusantibodiesobtained
from PV patients. This phenomenon is strongly inhibited
after subsequent incubation of keratinocytes with anti-TNF-
α and anti-IL1α antibodies [15].
D’Auria et al. [3] also showed a positive correlation
between serum concentration of these cytokines and the
number of skin lesions. In our study, we attempted to
assess TNF-α, IL-1, and IL-6 sera concentrations in PV
patients being either in the active stage of the disease or
in clinical remission. In the patients presenting the active
stage of the disease, only IL-6 serum concentration was
signiﬁcantly higher when compared to the control group.
IL-1 and TNF-α serum levels did not diﬀer between patients
in the active stage and the controls. In the patients who
were in clinical remission, we found similar results. Only
IL-6 serum level was higher while the rest of the examined
cytokines presented similar values to the controls. Decreased
levels of IL-6 in remission stage of PV when compared to
theactivepatients(statisticallyinsigniﬁcant)mayresultfrom
the immunosuppressive treatment administration. In many
reports, it is noted that prednisone and cyclophosphamide
inﬂuence proinﬂammatory cytokines levels, including IL-
6l e v e l s[ 16, 17]. Our results conﬁrm the role of IL-6
in PV pathogenesis, not only in the initial stage of the
disease development but also the pathophysiological process
maintenance. In most published studies, the authors found
an increased level of TNF-α in the active stage of pemphigus
[4]. TNF-α is a cytokine involved in the majority of inﬂam-
matory processes, and its increased activity is found in many
skin diseases including psoriasis, SLE, or systemic sclerosis
[18–20]. TNF-α is released by cells under various stimuli
includingbacterialinfectionsorultravioletradiation.Itplays
a role in many biological processes, enhances phagocytosis,
cytotoxicity, and modulates activity of other cytokines such
as IL-1 and IL-4 [21]. We did not conﬁrm TNF-α increased
concentrationinPVpatientswhencomparedtothecontrols.
However, its negative correlation with pemphigus antibodies
titer and relatively increased values when compared to
the controls (no statistical signiﬁcance) may suggest its
involvementinmaintainingpathologicalmechanisms.Treat-
ment with immunosuppressive agents is suﬃcient to reduce
skin lesions formation and decrease antibodies production,
however it probably does not inﬂuence disturbed cellular
response. These data also partially explain why anti-TNF-α
treatment is successful in refractory PV patients.
There is only a scarcity of data on cytokines’ levels in sera
of PV patients in clinical remission. Bhol et al. [22] revealed
a marked reduction of IL-1α and IL-1β with simultaneously
increased levels of IL-1R in sera of patients in clinical
remission. Intravenous immunoglobulin (IVIG) therapy
caused similar eﬀects thus suggesting that its therapeutic
eﬀect could depend on modulation of IL1 isoforms and
its receptor levels. Galle et al. [23] and Keskin et al. [17]
revealed also that IVIG exerts anti-IL-6 properties thus to
some extent, explaining mechanisms of its activity in PV
patients. IL-10 concentration in serum was also signiﬁcantly
lower in patients in clinical remission when compared to
the active ones and its values correlated with pemphigus
antibodies titers [24]. To the best of our knowledge, there
is no data on IL-6 serum concentration in the PV patients
in clinical remission. Our data suggest the role of IL-6 in
the immunological disturbances maintenance in remission
stage of PV, namely, in the patients in whom, despite lack of
clinical lesions, antibodies are still produced and possess the
ability to bind to keratinocytes surface antigens. We believe
that this observation suggests clinical application of anti-IL-
6 antibodies in refractory cases of pemphigus vulgaris.
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